NCT01734278View on ClinicalTrials.gov

Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2018

Conditions
Manic Disorder
Interventions
OTHER

No intervention

This is a non-interventional study.

Trial Locations (1)

ST16 3SR

South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Professor Saad Shakir

OTHER

NCT01734278 - Observational Post-Authorisation Safety Study of Asenapine (Sycrest) | Biotech Hunter | Biotech Hunter